

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/521,768	01/19/2005	Robert Kallmeier	4145-22	4166
23117 75 NIXON & VAN	590 03/16/200 DERHYE, PC	EXAMINER		
901 NORTH GLEBE ROAD, 11TH FLOOR			QIAN, CELINE X	
ARLINGTON, VA 22203			ART UNIT	PAPER NUMBER
			1636	
			_	
SHORTENED STATUTORY	PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE	
31 DAYS		03/16/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

		Application No.	Applicant(s)			
Office Action Summary		10/521,768	KALLMEIER ET AL.			
		Examiner	Art Unit			
	·	Celine X. Qian Ph.D.	1636			
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1)	Responsive to communication(s) filed on					
· —		action is non-final.				
,—	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
,	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Dispositi	on of Claims					
4)⊠	4)⊠ Claim(s) <u>9-23</u> is/are pending in the application.					
	4a) Of the above claim(s) is/are withdrawn from consideration.					
5)	5) Claim(s) is/are allowed.					
6)	6) Claim(s) is/are rejected.					
7)	7) Claim(s) is/are objected to.					
8)⊠	Claim(s) 9-23 are subject to restriction and/or e	election requirement.				
Application Papers						
9)☐ The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority u	ınder 35 U.S.C. § 119					
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No.</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>						
Attachment(s)						
	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summary Paper No(s)/Mail Da				
3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date  5) Notice of Informat Patent Application 6) Other:						

Application/Control Number: 10/521,768

Art Unit: 1636

## **DETAILED ACTION**

Claims 9-23 are pending in the application.

## Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

- Group I, claims 9-15, drawn to a CHO cell comprising an expression vector comprising a promoter which is active in CHO cells driving the expression of a recombinant product protein and further comprises a portion from murine IgG 2A gene which enhances the activity of the promoter, and a method of producing a recombinant product protein by culturing said CHO cells.
- Group II, claim 16, drawn to a CHO cell comprising a mammalian expression vector comprising a first transcription unit with a product gene under the control of mCMV promoter, and a second transcription unit comprising a glutamine synthetase marker gene.
- Group III, claims 17-22, drawn to an expression vector comprising a first transcription unit with a product gene under the control of mCMV promoter, and a second transcription unit comprising a glutamine synthetase marker gene.
- Group IV, claim 23, drawn to a method of using 17 for enhancing the transfection rate in CHO cells.

Art Unit: 1636

PCT Rule 13.2 requires that unity of invention exists only when the shared same or corresponding technical feature is a contribution over the prior art. The inventions listed as Groups I-IV do not relate to a single general inventive concept because they lack the same or corresponding special technical feature. The "special technical feature" of Group I is a CHO cell comprising a vector that comprises a portion of the murine IgG 2A gene locus DNA, which not shared by the rest of the groups. The special technical feature of Group II is a CHO cell comprising a mammalian expression vector comprising a first transcription unit for a product gene and a second transcription unit comprising a glutamine synthetase marker gene, which is not shared by the remaining groups. The special technical feature of Group III is a comprising a mammalian expression vector comprising a first transcription unit for a product gene under the control of mCMV, and a second transcription unit comprising a glutamine synthetase marker gene, which is not share by the remaining groups. The special technical feature of Group IV is a method of using 17 for enhancing the transfection rate in CHO, which is not shared by the remaining groups. As such, the technical feature of each group is different, and cannot link the invention as a whole to form a single general inventive concept under PCT Rule 13.1.

Therefore, the unity of invention does not exit between the claims of Groups I-IV.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and

specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Celine X. Qian Ph.D. whose telephone number is 571-272-0777. The examiner can normally be reached on 9:30-6:00 M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Remy Yucel Ph.D. can be reached on 571-272-0781. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/521,768

Art Unit: 1636

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Celine X Qian Ph.D. Examiner Art Unit 1636 Page 5

CELINE QIAN, PH.D. PRIMARY EXAMINER